Medtronic (MDT) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Dec 1, 2026 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Geoffrey Martha, CEO, Chair sold 50,000 shares at $95.00 ($4.8M).
- Trade date
- Oct 15, 2026
- Disclosed to the SEC
- Oct 16, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All MDT insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
MDT insider transactions (Form 4)
Open-market purchases and sales. 64 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 16SEC | Geoffrey MarthaCEO, Chair | Sell Plan | 50,000277,866 held (−15%) | $95.00 | $4.8M | +5.9% | — |
| Oct 16SEC | Michael MarinaroEvp, Pres Medsurg And Americas | Sell Plan | 10,420105,916 held (−9%) | $96.00 | $1.0M | +4.8% | — |
| Sep 17SEC | Harry Skip KiilPresident | Sell | 1,48342,186 held (−3%) | $93.65 | $139K | +7.4% | — |
| Jul 9SEC | Matthew R. WalterSvp, Chief Hr Officer | Sell Plan | 3,10235,694 held (−8%) | $83.15 | $258K | +21.0% | — |
| Jun 9SEC | Harry Skip KiilPresident | Sell | 3,96137,455 held (−10%) | $80.44 | $319K | +25.0% | — |
| Jun 9SEC | Harry Skip KiilPresident | Sell | 22837,227 held (−1%) | $80.45 | $18K | +25.0% | — |
| Feb 26SEC | Harry Skip KiilPresident | Sell | 30,56853,076 held (−37%) | $97.66 | $3.0M | +3.0% | — |
| Feb 26SEC | Harry Skip KiilPresident | Sell | 19,25533,821 held (−36%) | $97.77 | $1.9M | +2.9% | — |
| Feb 26SEC | Harry Skip KiilPresident | Sell | 1,64883,644 held (−2%) | $97.86 | $161K | +2.8% | — |
| Feb 26SEC | Harry Skip KiilPresident | Sell | 66833,153 held (−2%) | $97.83 | $65K | +2.8% | — |
| Feb 26SEC | Harry Skip KiilPresident | Sell | 38532,768 held (−1%) | $97.82 | $38K | +2.8% | — |
| Nov 21SEC | Gregory L. SmithEvp Global Ops & Supply Chain | Sell | 24,18651,830 held (−32%) | $101.93 | $2.5M | -1.3% | — |
| Nov 21SEC | Gregory L. SmithEvp Global Ops & Supply Chain | Sell | 1,99547,893 held (−4%) | $102.03 | $204K | -1.4% | — |
| Nov 21SEC | Gregory L. SmithEvp Global Ops & Supply Chain | Sell | 1,94249,888 held (−4%) | $101.99 | $198K | -1.4% | — |
| Nov 21SEC | Gregory L. SmithEvp Global Ops & Supply Chain | Sell | 82547,068 held (−2%) | $102.04 | $84K | -1.4% | — |
| Nov 21SEC | Gregory L. SmithEvp Global Ops & Supply Chain | Sell | 50046,016 held (−1%) | $102.08 | $51K | -1.5% | — |
| Nov 21SEC | Gregory L. SmithEvp Global Ops & Supply Chain | Sell | 32546,516 held (−1%) | $102.06 | $33K | -1.5% | — |
| Nov 21SEC | Gregory L. SmithEvp Global Ops & Supply Chain | Sell | 22746,841 held (−0%) | $102.05 | $23K | -1.4% | — |
Similar past setups: not applicable. MDT has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with MDT in the Research Lab
MDT has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Medtronic insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $14.7M of MDT stock on the open market; P/E 21.6 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
MDT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $5.8M | 2 |
| Q3 2026 | — | 0 | $397K | 2 |
| Q2 2026 | — | 0 | $337K | 2 |
| Q1 2026 | — | 0 | $5.1M | 5 |
| Q4 2025 | — | 0 | $3.1M | 7 |
Valuation, profit and volume
Source: Yahoo Finance, as of Oct 5, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Medtronic insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $14.7M. 3 of 18 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
MDT earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Sep 1, 2026 | -0.7% | None | +1.7%S&P -0.2% | -5.5% |
| Jun 3, 2026 | -4.6% | None | +11.1%S&P -0.3% | +2.5% |
| Feb 17, 2026 | -1.5% | None | -1.0%S&P +0.7% | -12.5% |
| Nov 18, 2025 | +6.2% | None | +4.2%S&P -0.5% | -1.7% |
| Aug 19, 2025 | +3.9% | None | +0.4%S&P -0.8% | +2.0% |
| May 21, 2025 | +3.5% | None | -6.3%S&P -1.6% | +6.7% |
| Feb 18, 2025 | +0.9% | None | -6.3%S&P +0.5% | +3.8% |
| Nov 19, 2024 | -2.8% | None | -4.0%S&P +0.4% | -3.7% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
MDT short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded MDT
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Thomas H TubervilleSenate | Sold $15,001 - $50,000 | Aug 26, 2024 | Aug 5, 2026 | +21.1% |
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +17.4% |
Insiders at Medtronic
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Harry Skip KiilPresident | — | $5.6M | Sep 17, 2026 | — | — |
| Geoffrey MarthaCEO, Chair | — | $4.8M | Oct 16, 2026 | — | — |
| Gregory L. SmithEvp Global Ops & Supply Chain | — | $3.1M | Nov 21, 2025 | — | — |
| Michael MarinaroPresident | — | $1.0M | Nov 4, 2026 | — | — |
| Matthew R. WalterSvp, Chief Hr Officer | — | $258K | Aug 4, 2026 | — | — |
| Kevin E. LoftonDirector | — | — | Oct 21, 2026 | — | — |
| Denise L. BlomquistChief Accounting Officer | — | — | Sep 16, 2026 | — | — |
| Kweli ThompsonPresident | — | — | Aug 4, 2026 | — | — |
| Michelle QuinnEvp, Gc And Secretary | — | — | Aug 4, 2026 | — | — |
| Thierry PietonCFO | — | — | Aug 4, 2026 | — | — |
| Brett A. WallEvp & Pres Neuroscience | — | — | May 28, 2026 | — | — |
| Craig ArnoldDirector | — | — | Apr 29, 2026 | — | — |
| Randall J. HoganDirector | — | — | Apr 29, 2026 | — | — |
| Scott C. DonnellyDirector | — | — | Apr 29, 2026 | — | — |
| Kendall J. PowellDirector | — | — | Apr 29, 2026 | — | — |
| Lidia FonsecaDirector | — | — | Apr 29, 2026 | — | — |
| Elizabeth G. NabelDirector | — | — | Apr 29, 2026 | — | — |
| Gregory P. LewisDirector | — | — | Apr 29, 2026 | — | — |
| William R. JellisonDirector | — | — | Apr 29, 2026 | — | — |
| John P. GroetelaarsDirector | — | — | Apr 29, 2026 | — | — |
| Joon Sup LeeDirector | — | — | Apr 29, 2026 | — | — |
Board links: companies that share insiders with MDT
Directors and executives who filed Form 4s for MDT and another company in the last 12 months.
- HONHoneywell Technologies Craig Arnold Director here · Director at HON · latest filing Apr 29, 2026
- HONAHoneywell Aerospace Craig Arnold Director here · Director at HONA · latest filing Sep 3, 2026
- KGSKodiak Gas Services Randall J. Hogan Director here · Director at KGS · latest filing Nov 18, 2026
- KKRKKR Craig Arnold Director here · Director at KKR · latest filing Apr 29, 2026
- MRNAModerna Elizabeth G. Nabel Director here · Director at MRNA · latest filing May 4, 2026
- NEENextEra Energy Geoffrey Martha CEO, Chair here · Director at NEE · latest filing Oct 16, 2026
- PFEPfizer Lidia Fonseca Director here · President at PFE · latest filing Apr 29, 2026
- PGProcter & Gamble Craig Arnold Director here · Director at PG · latest filing Oct 14, 2026
- TXTTextron Scott C. Donnelly Director here · Chair at TXT · latest filing Apr 29, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
MDT stock: common questions
Are Medtronic insiders buying MDT stock?
No. No Medtronic insider reported an open-market purchase of MDT in the past 12 months.
Are Medtronic insiders selling MDT stock?
5 insiders reported sales worth $14.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is MDT's P/E ratio?
MDT trades at about 21.6 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is MDT's 52-week range?
Over the past year MDT has traded between $72.50 and $104.96. It last closed at $100.58 on Nov 19, 2026.